Merck to Buy Terns for $6.7B to Grow in Blood Cancers
The Big Market Report Take
Bloomberg's Michelle Davis joins Dani Burger on "Bloomberg Deals." Merck agreed to buy Terns Pharmaceuticals for $6.7 billion, giving the multinational company access to a promising new leukemia treatment as it faces the patent expiration of its bestselling cancer drug. (Source: Bloomberg)
Not financial advice. The Big Market Report aggregates news for informational purposes only. Nothing on this site constitutes investment advice. Equities and other securities are subject to market risk. Always do your own research and consult a qualified financial advisor before making any investment decisions. Full disclaimer →
Never miss a story
More from this section
- The AI Chip Split - And Why Amazon Is On The Right SideSeeking Alpha10m ago
- Airbnb: AI Is An Opportunity, Not A ThreatSeeking Alpha11m ago
- JetBlue’s stock turns positive for the year on merger talkMarketWatch13m ago
- Stocks Rise as Truce Prospects Weighed | Closing BellBloomberg Markets17m ago
- Morgan Stanley Warns Dollar Rally Won’t Last Long Amid Iran WarBloomberg Markets25m ago